Malignant transformation in a defined genetic background: Proteome changes displayed by 2D-PAGE

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Pütz, Stephanie M ^a,b   Vogiatzi, Fotini ^c   Stiewe, Thorsten ^c   Sickmann, Albert ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; CYTOKERATIN 7; HEAT SHOCK PROTEIN 90; LIPOCORTIN 2; PEROXIREDOXIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEOME; PROTEIN P21; TELOMERASE;

AMINO ACID SEQUENCE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING; CELL LINE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PATHOLOGY; SIMIAN VIRUS 40; TANDEM MASS SPECTROMETRY;

SIMIAN VIRUS 40;

BLOTTING, WESTERN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEOME; PROTO-ONCOGENE PROTEINS P21(RAS); SIMIAN VIRUS 40; TANDEM MASS SPECTROMETRY; TELOMERASE;

EID: 77956840339     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-254     Document Type: Article

References (53)

1. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002, 108:135-144. 10.1016/S0092-8674(02)00621-9, 11832204.
2. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003, 3:952-959. 10.1038/nrc1235, 14737125.
3. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352. 10.1126/science.279.5349.349, 9454332.
4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015. 10.1126/science.7605428, 7605428.
5. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468. 10.1038/22780, 10440377.
6. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001, 15:50-65. 10.1101/gad.828901, 312602, 11156605.
7. Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, Olsen JC, Miller SW, Weinberg RA, Hahn WC. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002, 21:4577-4586. 10.1038/sj.onc.1205550, 12085236.
8. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MA. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 2002, 21:4200-4211. 10.1038/sj.onc.1205425, 12082607.
9. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Res 2001, 61:3556-3560.
10. Yu J, Boyapati A, Rundell K. Critical role for SV40 small-t antigen in human cell transformation. Virology 2001, 290:192-198. 10.1006/viro.2001.1204, 11883184.
11. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, Weinberg RA. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002, 22:2111-2123. 10.1128/MCB.22.7.2111-2123.2002, 133688, 11884599.
12. Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 2003, 4:311-319. 10.1016/S1535-6108(03)00223-X, 14585358.
13. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, Sears R. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004, 6:308-318. 10.1038/ncb1110, 15048125.
14. Rodriguez-Viciana P, Collins C, Fried M. Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci USA 2006, 103:19290-19295. 10.1073/pnas.0609343103, 1748219, 17158797.
15. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993, 75:887-897. 10.1016/0092-8674(93)90533-V, 8252625.
16. Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A, Stiewe T. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. Embo J 2008, 27:792-803. 10.1038/emboj.2008.13, 2265751, 18239687.
17. Görg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685. 10.1002/pmic.200401031, 15543535.
18. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250:4007-4021. 2874754, 236308.
19. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975, 26:231-243.
20. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001, 61:4956-4960.
21. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602. 10.1016/S0092-8674(00)81902-9, 9054499.
22. Dieckmann-Schuppert A, Schnittler HJ. A simple assay for quantification of protein in tissue sections, cell cultures, and cell homogenates, and of protein immobilized on solid surfaces. Cell Tissue Res 1997, 288:119-126. 10.1007/s004410050799, 9042779.
23. Lamanda A, Zahn A, Roder D, Langen H. Improved Ruthenium II tris (bathophenantroline disulfonate) staining and destaining protocol for a better signal-to-background ratio and improved baseline resolution. Proteomics 2004, 4:599-608. 10.1002/pmic.200300587, 14997483.
24. Moebius J, Denker K, Sickmann A. Ruthenium (II) tris-bathophenanthroline disulfonate is well suitable for Tris-Glycine PAGE but not for Bis-Tris gels. Proteomics 2007, 7:524-527. 10.1002/pmic.200600642, 17309097.
25. Sickmann A, Dormeyer W, Wortelkamp S, Woitalla D, Kuhn W, Meyer HE. Towards a high resolution separation of human cerebrospinal fluid. Journal of Chromatography B 2002, 771:167-196.
26. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
27. Braun RJ, Kinkl N, Beer M, Ueffing M. Two-dimensional electrophoresis of membrane proteins. Anal Bioanal Chem 2007, 389:1033-1045. 10.1007/s00216-007-1514-6, 17680235.
28. Westermeier R, Marouga R. Protein detection methods in proteomics research. Biosci Rep 2005, 25:19-32. 10.1007/s10540-005-2845-1, 16222417.
29. Richert S, Luche S, Chevallet M, Van Dorsselaer A, Leize-Wagner E, Rabilloud T. About the mechanism of interference of silver staining with peptide mass spectrometry. Proteomics 2004, 4:909-916. 10.1002/pmic.200300642, 15048973.
30. Winkler C, Denker K, Wortelkamp S, Sickmann A. Silver- and Coomassie-staining protocols: detection limits and compatibility with ESI MS. Electrophoresis 2007, 28:2095-2099. 10.1002/elps.200600670, 17516579.
31. Rabilloud T, Strub JM, Luche S, van Dorsselaer A, Lunardi J. A comparison between Sypro Ruby and ruthenium II tris (bathophenanthroline disulfonate) as fluorescent stains for protein detection in gels. Proteomics 2001, 1:699-704. 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.0.CO;2-C, 11678039.
32. Young T, Mei F, Liu J, Bast RC, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 2005, 24:6174-6184. 10.1038/sj.onc.1208753, 1201440, 15940260.
33. Chen WQ, Kang SU, Lubec G. Protein profiling by the combination of two independent mass spectrometry techniques. Nat Protoc 2006, 1:1446-1452. 10.1038/nprot.2006.246, 17406433.
34. Lottspeich F, Engels JW. Bioanalytik 2006, München: Spektrum, 2.
35. Ahuja D, Saenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24:7729-7745. 10.1038/sj.onc.1209046, 16299533.
36. MacKenzie KL, Franco S, May C, Sadelain M, Moore MA. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 2000, 259:336-350. 10.1006/excr.2000.4982, 10964501.
37. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 1999, 96:3723-3728. 10.1073/pnas.96.7.3723, 22361, 10097104.
38. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MA. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 2002, 21:4200-4211. 10.1038/sj.onc.1205425, 12082607.
39. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007, 9:R76. 10.1186/bcr1789, 2246172, 17980029.
40. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:6415-6420. 10.1158/1078-0432.CCR-06-1315, 17085654.
41. Manevich Y, Fisher AB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 2005, 38:1422-1432. 10.1016/j.freeradbiomed.2005.02.011, 15890616.
42. Noble M, Mayer-Proschel M, Proschel C. Redox regulation of precursor cell function: insights and paradoxes. Antioxid Redox Signal 2005, 7:1456-1467. 10.1089/ars.2005.7.1456, 16356108.
43. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995, 86:4007-4024.
44. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Febs J 2005, 272:4858-4867. 10.1111/j.1742-4658.2005.04879.x, 16176260.
45. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10:39-49. 10.2174/1381612043453559, 14754404.
46. Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003, 23:6520-6532. 10.1128/MCB.23.18.6520-6532.2003, 193706, 12944478.
47. Chen CF, Chen Y, Dai K, Chen PL, Riley DJ, Lee WH. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol Cell Biol 1996, 16:4691-4699. 231469, 8756626.
48. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270. 10.1016/j.cell.2007.08.028, 17956728.
49. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217. 10.1016/S1535-6108(03)00029-1, 12676580.
50. Souza-Rodrigues E, Estanyol JM, Friedrich-Heineken E, Olmedo E, Vera J, Canela N, Brun S, Agell N, Hubscher U, Bachs O, Jaumot M. Proteomic analysis of p16(ink4a)-binding proteins. Proteomics 2007, 7:4102-4111. 10.1002/pmic.200700133, 17955473.
51. Hayes MJ, Merrifield CJ, Shao D, Ayala-Sanmartin J, Schorey CD, Levine TP, Proust J, Curran J, Bailly M, Moss SE. Annexin 2 binding to phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is regulated by the stress response pathway. J Biol Chem 2004, 279:14157-14164. 10.1074/jbc.M313025200, 1351152, 14734570.
52. Roberts K, Bhatia K, Stanton P, Lord R. Proteomic analysis of selected prognostic factors of breast cancer. Proteomics 2004, 4:784-792. 10.1002/pmic.200300633, 14997499.
53. Ramos-Vara JA, Miller MA, Boucher M, Roudabush A, Johnson GC. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors. Vet Pathol 2003, 40:55-62. 10.1354/vp.40-1-55, 12627713.